Proteona Selected Among Top 20 Startups for MedTech Innovator Asia Pacific Showcase

Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology

SINGAPORE, 18 September 2019 - Proteona Pte. Ltd. has been selected as one of the 20 best-in-class startups for the inaugural MedTech Innovator Asia Pacific Showcase, taking place in Singapore from 8th to 9th October. Proteona will present its ESCAPE™ single cell proteogenomic analysis technology, and how it can make a difference for advancing sophisticated cancer therapies such as cell therapy. Proteona will have the opportunity to present in front of key healthcare stakeholders and investors in the Asia Pacific region.

MedTech Innovator is the premier global nonprofit medtech competition and accelerator. The inaugural Asia Pacific Showcase is organized in partnership with the Asia Pacific Medical Technology Association. The showcase recognizes companies that fulfill a significant unmet healthcare need in the region. The showcase is part of the fifth Asia Pacific MedTech Forum.

Read the MedTech Innovator press release here.

Schedule a meeting

For media queries, please contact:

Dr. Andreas Schmidt

About Proteona

Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).